blog
A new treatment for adult moderate-to-severe plaque psoriasis, Taltz (or ixekizumab), has been approved by the U.S. Food and Drug Administration. The new injection treatment was formulated by Eli Lilly & Co., is expected to be released by the end of the year.
“Over 7 million people have been diagnosed with psoriasis, making it important to find a treatment that offers relief to the scaling and lesions associated with the condition,” mentions Dr. Adam Mamelak, a board certified Dermatologist at Sanova Dermatology in Austin, Texas. Plaque psoriasis is noted as the most common form of psoriasis, characterized by thick pink plaques and silver-like scale on the skin. This autoimmune disorder is known for causing inflammation, itching, and for causing significant emotional distress to those who have it.
“Taltz works by binding and blocking IL-17 in the body,” explains Dr. Mamelak. IL-17 is one of the molecules that mediates inflammation and leads to the generation of psoriasis plaques on the skin.
Studies demonstrated that 87-90% of patients saw significant improvement while on Taltz, while 35-42% actually saw a complete clearing of their disease after 12 weeks of treatment. “Biologic treatments for psoriasis continue to grow and improve, giving patients more and more options to manage their disease. It is exciting and really gratifying to see these developments. The emphasis continues to be placed on offering the best treatment for psoriasis patients and those suffering from this skin disease,” continues Dr. Mamelak.
Sanova Dermatology strives to provide its patients with optimal and individualized care for all of their skin conditions and needs. If you suffer from psoriasis or have questions about treatment options, please contact us.